Elevated anti-apolipoprotein A-1 (AAA1) antibody levels associated with cardiovascular risk have been observed in previously SARS-CoV-2-infected or COVID-19-vaccinated individuals. Since patient safety is generally a priority in vaccination, we sought to investigate AAA1 antibody levels in healthy adults after mRNA vaccination. We conducted a prospective cohort study in healthy adult volunteers recruited from military workers of the Transport Air Base in Prague who had received two doses of mRNA vaccines. Anti-apolipoprotein A-1 antibody levels were determined using ELISA from serum samples obtained at three and four time points after the first and second vaccine doses, respectively, within almost 17 weeks of follow-up. The transient AAA1 positivity rate achieved 24.1% (95% confidence interval CI: 15.4-34.7%), i.e., 20 out of 83 participants had at least one positive post-vaccination sample, with a repeat positivity confirmed in only 5 of them. This rate was associated with a BMI > 26 kg/m2, as documented by an adjusted odds ratio of 6.79 (95% CI: 1.53-30.01). In addition, the highest positivity rate of 46.7% (21.3-73.4%) was observed in obese subjects with >30 kg/m2. Since the incidence rate of AAA1 positivity remained unchanged after the first and second vaccine doses, any relationship between AAA1 positivity and mRNA vaccination was inconclusive. The present study showed a transient AAA1 positivity rate associated with overweight or obesity without a proven association with mRNA vaccination.

1st Faculty of Medicine Charles University and Military University Hospital 121 08 Prague Czech Republic

3rd Faculty of Medicine Charles University 100 00 Prague Czech Republic

Institute for Clinical and Experimental Medicine 140 21 Prague Czech Republic

Institute of Aviation Medicine 160 00 Prague Czech Republic

Královské Vinohrady University Hospital 100 34 Prague Czech Republic

See more in PubMed

Munro A.P.S., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dodd K., et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 NCoV-19 or BNT162b2 in the UK (CoV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276. doi: 10.1016/S0140-6736(21)02717-3. PubMed DOI PMC

Stuart A.S.V., Shaw R.H., Liu X., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., Clutterbuck E.A., Collins A.M., et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating MRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-CoV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36–49. doi: 10.1016/S0140-6736(21)02718-5. PubMed DOI PMC

Adjobimey T., Meyer J., Sollberg L., Bawolt M., Berens C., Kovačević P., Trudić A., Parcina M., Hoerauf A. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, biontech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines. Front. Immunol. 2022;13:917905. doi: 10.3389/fimmu.2022.917905. PubMed DOI PMC

Petráš M., Lesná I.K., Dáňová J., Čelko A.M. Can vaccination trigger autoimmune disorders? A meta-analysis. Vaccines. 2021;9:821. doi: 10.3390/vaccines9080821. PubMed DOI PMC

Lai Y.-H., Chen H.-Y., Chiu H.-H., Kang Y.-N., Wong S.-B. Peripheral nervous system adverse events after the administration of MRNA vaccines: A systematic review and meta-analysis of large-scale studies. Vaccines. 2022;10:2174. doi: 10.3390/vaccines10122174. PubMed DOI PMC

Collantes M.E.V., Espiritu A.I., Sy M.C.C., Anlacan V.M.M., Jamora R.D.G. Neurological manifestations in COVID-19 infection: A systematic review and meta-analysis. Can. J. Neurol. Sci. 2021;48:66–76. doi: 10.1017/cjn.2020.146. PubMed DOI PMC

Hafeez M.U., Ikram M., Shafiq Z., Sarfraz A., Sarfraz Z., Jaiswal V., Sarfraz M., Chérrez-Ojeda I. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): A systematic review and post hoc analysis. Clin. Appl. Thromb. Hemost. 2021;27:107602962110488. doi: 10.1177/10760296211048815. PubMed DOI PMC

Yasuhara J., Masuda K., Aikawa T., Shirasu T., Takagi H., Lee S., Kuno T. Myopericarditis after COVID-19 MRNA vaccination among adolescents and young adults: A systematic review and meta-analysis. JAMA Pediatr. 2023;177:42. doi: 10.1001/jamapediatrics.2022.4768. PubMed DOI PMC

Li M., Wang X., Feng J., Feng Z., Li W., Ya B. Myocarditis or pericarditis following the COVID-19 vaccination in adolescents: A systematic review. Vaccines. 2022;10:1316. doi: 10.3390/vaccines10081316. PubMed DOI PMC

Gao J., Feng L., Li Y., Lowe S., Guo Z., Bentley R., Xie C., Wu B., Xie P., Xia W., et al. A systematic review and meta-analysis of the association between SARS-CoV-2 vaccination and myocarditis or pericarditis. Am. J. Prev. Med. 2023;64:275–284. doi: 10.1016/j.amepre.2022.09.002. PubMed DOI PMC

Vuilleumier N., Pagano S., Ludewig B., Schmiedeberg K., Haller C., Kempis J., Rubbert-Roth A. Anti-SARS-CoV-2 MRNA vaccines as inducers of humoral response against apolipoprotein A-1? Eur. J. Clin. Investig. 2022;52:e13713. doi: 10.1111/eci.13713. PubMed DOI PMC

Pagano S., Yerly S., Meyer B., Juillard C., Suh N., Le Terrier C., Daguer J., Farrera-Soler L., Barluenga S., Piumatti G., et al. SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1. Eur. J. Clin. Investig. 2021;51:e13661. doi: 10.1111/eci.13661. PubMed DOI PMC

Batuca J.R., Ames P.R.J., Isenberg D.A., Delgado Alves J. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 2007;1108:137–146. doi: 10.1196/annals.1422.016. PubMed DOI

Ames P., Matsuura E., Batuca J., Ciampa A., Lopez L., Ferrara F., Iannaccone L., Delgado Alves J. High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus. 2010;19:711–716. doi: 10.1177/0961203309357765. PubMed DOI

Vuilleumier N., Bratt J., Alizadeh R., Jogestrand T., Hafström I., Frostegård J. Anti-ApoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): Potential associations with cardiovascular disease and RA disease activity. Scand. J. Rheumatol. 2010;39:447–453. doi: 10.3109/03009741003742755. PubMed DOI

Montecucco F., Vuilleumier N., Pagano S., Lenglet S., Bertolotto M., Braunersreuther V., Pelli G., Kovari E., Pane B., Spinella G., et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur. Heart J. 2011;32:412–421. doi: 10.1093/eurheartj/ehq521. PubMed DOI

Keller P.-F., Pagano S., Roux-Lombard P., Sigaud P., Rutschmann O.T., Mach F., Hochstrasser D., Vuilleumier N. Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. J. Intern. Med. 2012;271:451–462. doi: 10.1111/j.1365-2796.2011.02479.x. PubMed DOI

Adam S., Ho J.H., Liu Y., Siahmansur T., Iqbal Z., Pagano S., Azmi S., Dhage S.S., Donn R., Ammori B.J., et al. Bariatric surgery leads to a reduction in antibodies to apolipoprotein A-1: A prospective cohort study. Obes. Surg. 2022;32:355–364. doi: 10.1007/s11695-021-05738-7. PubMed DOI PMC

Rashid S., Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity. 2007;15:2875–2888. doi: 10.1038/oby.2007.342. PubMed DOI

Antiochos P., Marques-Vidal P., Virzi J., Pagano S., Satta N., Bastardot F., Hartley O., Montecucco F., Mach F., Waeber G., et al. Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population: Results from the Colaus study. Thromb. Haemost. 2016;116:764–771. doi: 10.1160/TH16-03-0248. PubMed DOI

Frias M.A., Virzi J., Batuca J., Pagano S., Satta N., Delgado Alves J., Vuilleumier N. ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. J. Immunol. Methods. 2019;469:33–41. doi: 10.1016/j.jim.2019.03.011. PubMed DOI